63 related articles for article (PubMed ID: 7530829)
1. Transformation of mouse cells by wild-type mouse c-Src.
Lin PH; Shenoy S; Galitski T; Shalloway D
Oncogene; 1995 Jan; 10(2):401-5. PubMed ID: 7530829
[TBL] [Abstract][Full Text] [Related]
2. Mutational activation of pp60(c-src) leads to a tumorigenic phenotype in a preneoplastic Syrian hamster embryo cell line.
Lansing TJ; Turk BF; Kanner SB; Gilmer TM
Cancer Res; 1997 May; 57(10):1962-9. PubMed ID: 9157992
[TBL] [Abstract][Full Text] [Related]
3. Induction of growth factor-independence and GM-CSF secretion by the v-src oncogene in murine myeloid cells does not require membrane association of pp60v-src.
Ostermeyer AG; Anderson SM
Exp Hematol; 1996 Feb; 24(2):176-84. PubMed ID: 8641339
[TBL] [Abstract][Full Text] [Related]
4. Morphological transformation, tumorigenicity and src-specific cytotoxic T-lymphocyte-mediated tumor immunity induced by murine 3T3 cells expressing src oncogenes encoding novel non-myristylated N-terminal domains.
Gelman IH; Khan S; Hanafusa H
Oncogene; 1993 Nov; 8(11):2995-3004. PubMed ID: 7692370
[TBL] [Abstract][Full Text] [Related]
5. Catalytic activity and transformation potential of v-Src require arginine 385 in the substrate binding pocket.
Senften M; Schenker G; Sowadski JM; Ballmer-Hofer K
Oncogene; 1995 Jan; 10(1):199-203. PubMed ID: 7529917
[TBL] [Abstract][Full Text] [Related]
6. Reexpression of the major protein kinase C substrate, SSeCKS, suppresses v-src-induced morphological transformation and tumorigenesis.
Lin X; Gelman IH
Cancer Res; 1997 Jun; 57(11):2304-12. PubMed ID: 9187136
[TBL] [Abstract][Full Text] [Related]
7. Role of c-Src in cellular events associated with colony-stimulating factor-1-induced spreading in osteoclasts.
Insogna K; Tanaka S; Neff L; Horne W; Levy J; Baron R
Mol Reprod Dev; 1997 Jan; 46(1):104-8. PubMed ID: 8981371
[TBL] [Abstract][Full Text] [Related]
8. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling.
Sinibaldi D; Wharton W; Turkson J; Bowman T; Pledger WJ; Jove R
Oncogene; 2000 Nov; 19(48):5419-27. PubMed ID: 11114718
[TBL] [Abstract][Full Text] [Related]
9. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model.
Wiener JR; Nakano K; Kruzelock RP; Bucana CD; Bast RC; Gallick GE
Clin Cancer Res; 1999 Aug; 5(8):2164-70. PubMed ID: 10473101
[TBL] [Abstract][Full Text] [Related]
10. Suppression of malignant growth potentials of v-Src-transformed human gallbladder epithelial cells by adenovirus-mediated dominant negative H-Ras.
Tokumitsu Y; Nakano S; Ueno H; Niho Y
J Cell Physiol; 2000 May; 183(2):221-7. PubMed ID: 10737897
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic changes induced by wild type and variant c-src genes carrying C-terminal sequence alterations.
Yatsula BA; Plachy J; Mikhailik A; David-Pfeuty T; Lecoq O; Yatsula V; Geryk J; Svoboda J; Calothy G; Dezélée P
Oncogene; 1996 Dec; 13(12):2717-25. PubMed ID: 9000146
[TBL] [Abstract][Full Text] [Related]
12. Delineating v-Src downstream effector pathways in transformed myoblasts.
Ciuffini L; Castellani L; Salvati E; Galletti S; Falcone G; Alemà S
Oncogene; 2008 Jan; 27(4):528-39. PubMed ID: 17637741
[TBL] [Abstract][Full Text] [Related]
13. Differential effect of the focal adhesion kinase Y397F mutant on v-Src-stimulated cell invasion and tumor growth.
Chang LC; Huang CH; Cheng CH; Chen BH; Chen HC
J Biomed Sci; 2005; 12(4):571-85. PubMed ID: 16132110
[TBL] [Abstract][Full Text] [Related]
14. Junctional intercellular communication is cooperatively inhibited by oncogenes in transformation.
Azarnia R; Mitcho M; Shalloway D; Loewenstein WR
Oncogene; 1989 Oct; 4(10):1161-8. PubMed ID: 2477782
[TBL] [Abstract][Full Text] [Related]
15. Modulation of prostaglandin G/H synthase expression in mesangial cells transfected by pp60c-src proto-oncogene.
Reiser CO; Marx M; Hoppe J; Goppelt-Struebe M
Exp Cell Res; 1996 Feb; 222(2):304-11. PubMed ID: 8598218
[TBL] [Abstract][Full Text] [Related]
16. Reduced phosphotyrosine binding by the v-Src SH2 domain is compatible with wild-type transformation.
Tian M; Martin GS
Oncogene; 1996 Feb; 12(4):727-34. PubMed ID: 8632894
[TBL] [Abstract][Full Text] [Related]
17. Binding in vitro of phosphotyrosine-containing proteins to pp60c-src SH2 domain does not correlate with CEF transformation.
Boeuf H; Murphy J; Bibbins KB; Varmus HE
Oncogene; 1995 Feb; 10(3):433-8. PubMed ID: 7531318
[TBL] [Abstract][Full Text] [Related]
18. Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion.
Xian W; Rosenberg MP; DiGiovanni J
Oncogene; 1997 Mar; 14(12):1435-44. PubMed ID: 9136987
[TBL] [Abstract][Full Text] [Related]
19. An increase in the expression and total activity of endogenous p60(c-Src) in several factor-independent mutants of a human GM-CSF-dependent leukemia cell line (TF-1).
Horn S; Meyer J; Stocking C; Ostertag W; Jücker M
Oncogene; 2003 Oct; 22(46):7170-80. PubMed ID: 14562045
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of metalloproteinase (gelatinase) activity secreted from Rous sarcoma virus-infected cells correlates with transforming activity of src.
Hamaguchi M; Yamagata S; Thant AA; Xiao H; Iwata H; Mazaki T; Hanafusa H
Oncogene; 1995 Mar; 10(6):1037-43. PubMed ID: 7535415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
